US Patent
US7960370 — Type A gelatin capsule containing PUFA in free acid form
Formulation · Assigned to Individual · Expires 2026-12-20 · 1y remaining
Vulnerability score
65/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects a soft gelatin capsule containing omega-3 polyunsaturated fatty acids in free acid form, made with gelatin extracted using an acid pre-treatment process.
USPTO Abstract
A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterized in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life.
Drugs covered by this patent
- Epanova (OMEGA-3-CARBOXYLIC ACIDS) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.